Гормонотерапия в акушерстве и гинекологии. Иллюзии и реальность

Evans J., Salamonsen L. A. Inflammation, leukocytes and menstruation. Rev. Endocr. Metab. Disord., 2012; 13:277–288.

Evans R. M. The steroid and thyroid hormone receptor superfamily. Science, 1988; 240:889–895.

Facchinetti F., et al. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am. J. Obstet. Gynecol., 2007; 196 (5):453.e1–453.e4.

Falsetti C., et al. Decreased responsiveness to progesterone of spermatozoa in oligozoospermic patients. J. Androl., 1993; 14:17–22.

Fanchin R., et al. Transvaginal administration of progesterone. Obstet. Gynecol., 1997; 90:396–401.

Fanchin R., et al. Hormonal influence on the uterine contractility during ovarian stimulation. Hum. Reprod., 2000; 15:90–100.

Fanchin R., et al. Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Hum. Reprod.,1998; 13:1968–1974.

Fanhin R., et al. Premature elevation of plasma progesterone alters pregnancy rates of in vitro fertilization and embryo transfer. Fertil. Steril., 1993; 59:1090–1094.

Farine D., Mundle W. R., Dodd J. The use of progesterone for prevention of preterm birth. J. Obstet. Gynecol. Can., 2008; 30:67–71.

Farquaharson R. G., Klopper A. I. Progesterone concentrations in maternal and fetal blood. BJOG, 1984; 91:133–137.

Fatemi H. M., et al. An update of luteal phase support in stimulated IVF cycles. Hum. Reprod. Update, 2007; 13:581–590.

Fauser B. C., Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol. Metab., 2003; 14:236–242.

Faust Z., et al. Progesterone induced blocking factor inhibits degranulation of NK cells. Am. J. Reprod. Immunol., 1999; 42:71–75.

Fazleabas A. T. Progesterone resistance in a baboon model of endometriosis. Sem. Reproduc. Med., 2010; 28:75–80.

Fechner P. Y., et al. The role of the sex-determining region Y gene in the etiology of 46,XX maleness. J. Clinical Endocrine Metabolism, 1993; 76:690–695.

Ferencz C., et al. Maternal hormone therapy and congenital heart disease. Teratology, 1980; 21:225–239.

Ferin M. Neuroendocrine control of ovarian function in the primate. J. Reprod. Fertil., 1983; 69:369–81.

Ferre F., et al. Oral administration of micronized natural progesterone in late human pregnancy. Effects on progesterone and estrogen concentrations in the plasma, placenta, and myometrium. Am. J. Obstet. Gynecol., 1984; 148:26–34.

Ferretti G., Felici A., Cognetti F. The protective side of progesterone. Breast Cancer Research, 2007; 9:402.

Fetal effects of exogenous progesteroine. Birth Defects Research (Part B), 2006; 77:455–470.

Fiad T. M., Cunningham S. K., McKenna T. J. Role of P deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome. Eur. J. Endocrinol., 1996; 135:335–339.

Files J. A., Ko M. G., Pruthi S. Bioidentical Hormone Therapy Concise review for clinicians. Mayo Clin. Proc., 2011; 86 (7):673–680.

Filicori M., Butler J. P., Crowley W. F. Jr. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. J. Clin. Invest., 1984; 73:1638–1647.

Fisch H., et al. Maternal age as a risk factor for hypospadias. J. Urol., 2001; 165:934–936.

Fitzpatrick L. A., Good A. Micronized progesterone: clinical indications and comparison with current treatments. Fertil. Steril., 1999; 72:389 –97.

Fitzpatrick L. A., Pace C., Wiita B. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J. Womens Health Gend. Based Med., 2000; 9 (4):381–7.

Fleming R., et al. Spontaneous follicular and luteal function in infertile women with oligomenorrhoea: role of luteinizing hormone. Clin. Endocrinol. (Oxf), 1995; 43:735–739.

Fomin V., Cox B., Word R. Effect of progesterone on intracellular Ca (2+) homeostasis on human myometrial smooth muscle cells. Am. J. Physiol., 1999; 276 (2, pt.1):C379–C385.

Fonseca E. B., et al. Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N. Engl. J. Med., 2007; 357 (5):462–469.

Food and Drug Administration. Bio-identicals: sorting myth from fact. US Food and Drug Administration. Web site. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm049311.htm.

Food and Nutrition Board. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macronutrients). Washington, DC: Institute of Medicine, 2005.

Foote W., Foote L. Influence of certain natural and synthetic steroids on genital development in guinea pigs. Fertil. Steril., 1964; 19:606–615.

Ford O., et al. Progesterone for premenstrual syndrome. Cochrane Database of Systematic Reviews, 2009. Issue 2. Art. No.:CD003415.